The Evidence for the Use of Growth Factors and Active Skin Substitutes for the Treatment of Non-Infected Diabetic Foot Ulcers (DFU): A Health Technology Assessment (HTA)

Abstract

Aims: Assessment of the safety, efficacy and effectiveness of growth factors alone or in combination with other technologies in the treatment of DFU including medical, economical, social, ethical and juridical aspects.

Methods: We systematically searched relevant data bases limited to English and German language and publications since 1990. Review and assessment of the quality of publications followed methods conforming to widely accepted standards for evidence-based medicine and health economics.

Results: We identified 25 studies comparing becaplermin, rhEGF, bFGF and the metabolically active skin grafts Dermagraft and Apligraf with standard wound care (SWC) alone or extracellular wound matrix. Study duration ranged from 12 to 20 weeks and the study population comprised between 17 and 382 patients. Treatment with becaplermin, rhEGF, Dermagraft and Apligraf resulted in a higher incidence of complete wound closure and shorter time to complete wound healing with statistically significant differences. Regarding the proportion of adverse events there was no difference between treatment groups. The methodological quality of the studies was affected by significant deficiencies. Economic evaluations showed becaplermin being cost-effective.

Conclusions: Add-on therapy with growth factors and active skin substitutes for treating uncomplicated DFU could be an alternative to SWC alone. For explicit recommendations further studies with stronger evidence are necessary.

Key words

diabetic foot - ulcer - growth factors - wound healing

References

• 1 Wild S, Roglic G, Green A. et al . Prevalence of diabetes: estimates for the year 2000 and projections for 2030.  Diabetes Care. 2004;  27 (10) 1047-1053
• 2 Bakker K, Riley P. The year of the diabetic foot.  DiabetesVoice. 2005;  50 (1) 11-14
• 3 World Health Organization WHO . World Diabetes Day: too many people are losing lower limbs unnecessarily to diabetes [cited 2010 Apr 15].  Available from http://www.who.int/mediacentre/news/releases/2005/pr61/en/index.html 2010; 
• 4 Buchberger B, Follmann M, Freyer D. et al . Bedeutung von Wachstumsfaktoren für die Behandlung von chronischen Wunden am Beispiel des diabetischen Fußulcus.  Köln: DAHTA@DIMDI; Available from http://portal.dimdi.de/de/hta/hta_berichte/hta262_bericht_de.pdf 2010; 
• 5 Moher D, Schulz KF, Altman DG. for the CONSORT group . The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials.  Lancet. 2001;  357 1191-1194
• 6 Siebert U, Behrend C, Mühlberger N. et al .Entwicklung eines Kriterienkataloges zur Beschreibung und Bewertung ökonomischer Evaluationsstudien in Deutschland. In: Leidl R, Schulenburg JM Graf von der, Wasem J (eds). Ansätze und Methoden der ökonomischen Evaluation – eine internationale Perspektive. Health Technology Assessment, Bd. 9. Baden-Baden: Nomos; 1999: 156-170
• 7 Marston WA, Hanft J, Norwood P for the Dermagraft Diabetic Foot Ulcer Study Group et al. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers. Results of a prospective randomized trial.  Diabetes Care. 2003;  26 1701-1705
• 8 Edmonds M. European and Australian Apligraf Diabetic Foot Ulcer Study Group . Apligraf in the treatment of neuropathic diabetic foot ulcers.  Int J Low Extrem Wounds. 2009;  8 (1) 11-18
• 9 Bhansali A, Venkatesh S, Dutta P. et al . Which is the better option: recombinant human PDGF-BB 0.01% gel or standard wound care, in diabetic neuropathic large plantar ulcers off-loaded by a customized contact cast?.  Diabetes Res Clin Pract. 2009;  83 (1) e13-e16
• 10 d’Hemecourt PA, Smiell JA, Karim MR. Sodium Carboxymethylcellulose Aqueous-Based Gel vs. Becaplermin Gel in Patients with Nonhealing Lower Extremity Diabetic Ulcers.  Wounds. 1998;  10 (3) 69-75
• 11 Hardikar JV, Chiranyeev Reddy Y, Deen Dayal Bung. et al and the HEALACE Study Group Efficacy of recombinant human platelet-derived growth factor (rhPDGF) based Gel in diabetic foot ulcers: A randomized, multicenter, double-blind, placebo-controlled study in India.  Wounds. 2005;  17 (6) 141-152
• 12 Steed and the Diabetic Ulcer Study Group . Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers.  J Vasc Surg. 1995;  21 (1) 71-81
• 13 Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (Becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study.  Diabetes Care. 1998;  21 (5) 822-827
• 14 Niezgoda JA, Van Gils CC, Frykberg RG and the Oasis Diabetic Ulcer Study Group et al. Randomized clinical trial comparing Oasis wound matrix to Regranex gel for diabetic ulcers.  Adv Skin Wound Care. 2005;  18 (5) 258-266
• 15 Tsang MW, Wong WKR, Hung CS. et al . Human epidermal growth factor enhances healing of diabetic foot ulcers.  Diabetes Care. 2003;  26 (6) 1856-1861
• 16 Viswanathan V, Pendsey S, Sekar N. et al . A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN-D^TM 150) in healing diabetic foot ulcers.  Wounds. 2006;  18 (7) 186-196
• 17 Richard JL, Parer-Richard C, Daures JP. et al . Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot. A pilot, randomized, double-blind, placebo-controlled study.  Diabetes Care. 1995;  18 (1) 64-69
• 18 Gentzkow GD, Iwasaki SD, Hershon KS. et al . Use of Dermagraft, a cultured human dermis, to treat diabetic foot ulcers.  Diabetes Care. 1996;  19 (4) 350-354
• 19 Hanft JR, Surprenant MS. Healing of chronic foot ulcers in diabetic patients treated with a human fibroblast-derived dermis.  J Foot Ankle Surg. 2002;  41 (5) 291-299
• 20 Pollak RA, Edington H, Jensen JL. et al and the Dermagraft Diabetic Ulcer Study Group A human dermal replacement for the treatment of diabetic foot ulcers.  Wounds. 1997;  9 (6) 175-183
• 21 Robson MC, Payne WG, Garner WL. et al . Integrating the results of phase IV (postmarketing) clinical trial with four previous trials reinforces the position that Regranex (becaplermin) Gel 0.01% is an effective adjunct to the treatment of diabetic foot ulcers.  J Appl Res. 2005;  5 (1) 35-45
• 22 Smiell JM, Wieman TJ, Steed DL. et al . Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies.  Wound Repair. 1999;  7 (5) 335-346
• 23 Ghatnekar O, Persson U, Willis M. et al . The cost-effectiveness in the UK of treating diabetic lower extremity ulcers with becaplermin gel.  J Drug Asses. 2000;  3 243-251
• 24 Ghatnekar O, Persson U, Willis M. et al . Cost Effectiveness of Becaplermin in the Treatment of Diabetic Foot Ulcers in Four European Countries.  Pharmacoeconomics. 2001;  19 (7) 767-778
• 25 Kantor J, Margolis DJ. Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis (Structured abstract).  Dermatol Surg. 2001;  27 (4) 347-351
• 26 Persson U, Willis M, Ödegaard K. et al . The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data (Structured abstract).  Value in Health. 2000;  3 39-46
• 27 Sibbald RG, Torrance G, Hux M. et al . Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers.  Ostomy Wound Manage. 2003;  49 (11) 76-84
• 28 Allenet B, Parée F, Lebrun T. et al . Cost-effectiveness modeling of Dermagraft for the treatment of diabetic foot ulcers in the French context.  Diabetes Metab. 2000;  26 (2) 125-132
• 29 Segal L, John S. The use of dermagraft in neuropathic foot ulcers in people with diabetes: an economic analysis in Australia.  Primary Intention. 10 (2) 49-57
• 30 Redekop WK, McDonnell J, Verboom P. et al . The cost effectiveness of Apligraf treatment of diabetic foot ulcers.  Pharmacoeconomics. 2003;  21 (16) 1171-1183
• 31 Steinberg J, Beusterien K, Plante K. et al . A cost analysis of a living skin equivalent in the treatment of diabetic foot ulcers.  Wounds. 2002;  14 142-149
• 32 Roehrig B, du Prel J-B, Blettner M. Studiendesign in der medizinischen Forschung Teil 2 der Serie zur Bewertung wissenschaftlicher Publikationen.  Dtsch Arztebl Int. 2009;  106 (11) 184-189
• 33 Schulz KF, Grimes DA. Blinding in randomised trials: hiding who got what.  Lancet. 2002;  359 696-700
• 34 Schulz KF, Grimes DA. Allocation concealment in randomised trials: defending against deciphering.  Lancet. 2002;  359 614-618
• 35 Higgins JPT, Green S. eds Assessment of study quality. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated 2006 September; cited 2010 Jan 05], section 6.  Available from: http://www.cochrane.org/sites/default/files/uploads/Handbook4.2.6Sep2006.pdf 2006; 
• 36 Steed DL. Clinical Evaluation of Recombinant Human Platelet-Derived Growth Factor for the Treatment of Lower Extremity Ulcers.  Plastic and Reconstructive Surgery. 2006;  117 (7S) 143-149 71–81
• 37 Steed DL, Donohoe D, Webster MW and the Diabetic Ulcer Study Group et al. Effect of extensive Debridement and Treatment on the Healing of Diabetic Foot Ulcers.  J Am Coll Surg. 1996;  183 61-64
• 38 Hinchliffe RJ, Valk GD, Apelqvist J. et al . A systematic review of the effectiveness of interventions to enhance the healing of chronic ulcers of the foot in diabetes.  Diabetes Metab Res Rev. 2008;  24 (S 01) S119-S144
• 39 Higgins J, Altmann DG. Assessing risk of bias in included studies. In: Higgins J, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 5.0.0. Oxford, UK: The Cochrane Collaboration; 2008

Correspondence